Connect with us

Health & Wellness

‘Digital dumpsites’ study highlights growing threat to children

Published

on

E-waste toxicants. Source: WHO

The health of children, adolescents and expectant mothers worldwide is at risk from the illegal processing of old electrical or electronic devices, the World Health Organization (WHO) said on Tuesday, in a landmark new report on the toxic threat. 

In a statement coinciding with the launch, WHO Director-General Tedros Adhanom Ghebreyesus warned that the health threat was growing, in line with the “mounting ‘tsunami of e-waste’”. 

“In the same way the world has rallied to protect the seas and their ecosystems from plastic and microplastic pollution, we need to rally to protect our most valuable resource –the health of our children – from the growing threat of e-waste”, he added. 

A growing pile 

Discarded electronic devices, or e-waste, has become the fastest growing domestic waste category in the world, according to the UN health agency.  

The Global E-waste Statistics Partnership (GESP) said that of the 53.6 million tonnes produced worldwide in 2019, only 17.4 per cent was recorded as collected and appropriately recycled.  

While the fate of the remaining e-waste is unknown, it is unlikely to have been managed and recycled in an environmentally-sound manner.  

Hazards on the heap 

While some e-waste ends up in landfills, significant amounts are often illegally shipped to low and middle-income countries where informal workers, including children and adolescents, pick through, dismantle, or use acid baths to extract valuable metals and materials from the discarded items. 

WHO said that an estimated 12.9 million women who work in the informal waste sector are potentially exposing themselves and their unborn children to toxic residue. 

Additionally, more than 18 million youngsters globally – and some as young as five – are said to be “actively engaged” in the wider industrial sector, of which e-waste processing is a small part.  

‘Devastating’ impact 

Informal methods of removing materials from e-waste have been linked to a range of health effects, especially in children, WHO said.  

Recycling e-waste particularly impacts those in vital stages of physical and neurological development, with children, adolescents and pregnant women most vulnerable. 

Children are more susceptible to the toxic chemicals because they absorb pollutants relative to their size and, with not-fully-developed organs, are less able than adults to eradicate harmful substances. 

“Improper e-waste management is…a rising issue that many countries do not recognize yet as a health problem”, said WHO lead author, Marie-Noel Brune Drisse, warning that if action is not taken now, “its impacts will have a devastating health effect on children and lay a heavy burden on the health sector in the years to come”.  

Call to action  

The Children and Digital Dumpsites report delves into the multiple dimensions of the problem, to practical action that the health sector and others concerned, can take to confront the insidious health risk.  

It calls for binding action by exporters, importers and governments to ensure environmentally sound disposal of e-waste and the health and safety of workers and communities. 

The health sector is also being asked to reduce adverse effects from e-waste by building up capacity to diagnose, monitor and prevent toxic exposure, and to advocate for better data and health research on risks faced by informal e-waste workers. 

“Children and adolescents have the right to grow and learn in a healthy environment, and exposure to electrical and electronic waste and its many toxic components unquestionably impacts that right”, said Maria Neira, WHO Director of the Department of Environment, Climate Change and Health.  

“The health sector can play a role by providing leadership and advocacy, conducting research, influencing policy-makers, engaging communities, and reaching out to other sectors to demand that health concerns be made central to e-waste policies.”

Continue Reading
Comments

Health & Wellness

COVID-19: WHO expresses hope worst of Omicron wave is over

Published

on

Omicron continues to sweep the world, but cases seem to have peaked in some countries, which gives the head of the World Health Organization (WHO) hope that the worst of this latest wave of COVID-19 is over. 

Briefing journalists in Geneva, Tedros Ghebreyesus said that more than 18 million cases were reported last week, and the pandemic itself is far from over, so no country is out of the woods yet.

The number of deaths remains stable, but the agency is concerned about the impact the variant is having on already exhausted health workers and overburdened health systems.

“I remain particularly concerned about many countries that have low vaccination rates, as people are many times more at risk of severe illness and death if they’re unvaccinated”, Tedros said. 

Omicron may be less severe, but for the WHO chief “the narrative that it is mild disease is misleading, hurts the overall response and costs more lives.”

Tedros noted that the virus is circulating “far too intensely with many still vulnerable” and argued that, for many countries, the next few weeks remain critical.

COVAX

Over the weekend, the UN-backed COVAX facility delivered its one-billionth dose of vaccine. 

Tedros said he was proud of the milestone, but believes it’s essential to keep forging ahead with distributing shots fairly, across the world. 

“Vaccines may be less effective at preventing infection and transmission of Omicron than they were for previous variants, but they still are exceptionally good at preventing serious disease and death”, he explained. 

For him, immunization continues to be “key to protecting hospitals from becoming overwhelmed.”

Tracking the virus

The WHO chief also highlighted the importance of tracking new variants, like Omicron, in real time.

Tedros believes that the pandemic is “nowhere near over” and, with the incredible growth of Omicron, new variants are likely to emerge

So far, more than 7 million whole genome sequences from 180 countries have been submitted to GISAID, a global mechanism that provides open access to genomic data and was initially set up to track flu.

Using all that data, new formulations of vaccines are being developed and assessed for how they perform against different strains. 

Despite those efforts, Tedros is concerned that the world will enter “a second and even more destructive phase of vaccine inequity”, if it doesn’t change course. 

New treatments 

Last Friday, WHO recommended two new COVID-19 treatmentsto fight severe illness and death: a rheumatoid arthritis drug called baricitinib and a monoclonal antibody called sotrovimab.

For Tedros, the challenge, once again, is that high prices and limited supply means access is limited.

WHO is currently working with its partners in ACT-Accelerator to negotiate lower prices with manufacturers and ensure supply will be available for low- and middle-income countries.

Meeting

Next week, the WHO Executive Board, which is made up of 34 Member States, will meet to discuss the world’s health challenges.

The pandemic will remain at the forefront, but Member States will also be discussing the devastating impact of the pandemic on other health issues, and how the backsliding can be stopped. 

According to the WHO chief, the agency willbe working to accelerate progress on negotiations around a global pandemic accord.

Cervical Cancer Awareness

On a final note, Tedros noted that January is Cervical Cancer Awareness month.

In 2020, an estimated 604,000 women were diagnosed with cervical cancer worldwide and about 342, 000 women died from the disease.

The main cause of the disease is infection with high-risk types of human papillomavirus (HPV), an extremely common family of viruses that are transmitted through sexual contact.

There are, however, vaccines that protect against high-risk HPV types, which means it should be one of the most preventable and treatable forms of cancer.

On Monday, Serbia announced that this year,it will introduce a vaccination programme against HPV, joining the 116 nationswho already do it. 

Continue Reading

Health & Wellness

UN-backed COVAX mechanism delivers its 1 billionth COVID-19 vaccine dose

Published

on

photo © UNICEF/Aimable Twiringiyima

With a 1.1 million jab delivery in Rwanda this weekend, the World Health Organization’s multilateral initiative to provide equal access to vaccines for all reached the one billion milestone.

Along with the Coalition for Epidemic Preparedness Innovations (CEPI), the Vaccine Alliance GAVI, and partners, WHO has led the largest vaccine procurement and supply operation in history with deliveries to 144 countries to date.

According to a press release published on Sunday, as of 13 January 2022, out of 194 countries members of WHO, 36 have vaccinated less than 10% of their population, and 88 less than 40%.

COVAX’s ambition was compromised by hoarding/stockpiling in rich countries, catastrophic outbreaks leading to borders and supply being locked. And a lack of sharing of licenses, technology, and know-how by pharmaceutical companies meant manufacturing capacity went unused”, the agency explained.

On 24 February 2021, Ghana became the first country in the world to receive vaccines through COVAX when 600,000 doses of the Oxford–AstraZeneca vaccine were delivered to Accra. 

The work that remains

COVAX is currently working with governments, manufacturers and partners to ensure that when countries receive vaccines, they can get them to people quickly.

“The work that has gone into this (1 billion) milestone is only a reminder of the work that remains”, the UN’s health agency underscored.

They added that with updated vaccines in the pipeline, citizens should demand that governments and pharmaceutical companies share health tools globally and “bring an end to the death and destruction cycles of this pandemic, limit new variants and drive a global economic recovery”.

COVAX is one of three pillars of the Access to COVID-19 Tools (ACT) Accelerator, which was launched by WHO in April 2020 in response to the pandemic.

The ACT Accelerator is a ground-breaking global collaboration to accelerate the development, production, and equitable access to COVID-19 tests, treatments, and vaccines. 

Continue Reading

Health & Wellness

WHO recommends two new drugs to treat patients with COVID-19 

Published

on

Around two million doses of Sotrovimab are being produced globally in the first half of 2022. © GlaxoSmithKline

The World Health Organization (WHO) on Thursday reccommended two new drugs to treat patients with COVID-19, one for patients with critical disease, and another deemed effective for non-severe cases.

The first drug, baricitinib, is a Janus kinase (JAK) inhibitor- a class of drugs used to treat autoimmune conditions, blood and bone marrow cancers, and rheumatoid arthritis.

According to the WHO Guideline Development Group, it is “strongly recommended” for patients with severe or critical disease in combination with corticosteroids.

The group of international experts based their recommendation on “moderate certainty evidence” that it improves survival and reduces the need for ventilation.

There was no observed increase in adverse effects.

The experts note that it has a similar effectas other arthritis drugs called interleukin-6 (IL-6) inhibitors. Because of that, when both drugs are available, they suggest choosing the best option based on cost, availability, and clinician experience.

It is not recommended to use both drugs at the same time.

The experts also advise against the use of two other JAK inhibitors (ruxolitinib and tofacitinib) for patients with severe or critical cases of COVID-19 infection.

According to them, trials undergone using these drugs failed to show any benefits arising using either drug,and suggested a possible increase in serious side effects with tofacitinib.

Non-severe cases

In the same update, WHO makes a conditional recommendation for the use of a monoclonal antibody known as sotrovimab in patients with non-severe cases.

According to them, the drug should only be administered to patients at the highest risk of hospitalisation. In those at lower risk, it onlyshowed “trivial benefits”. 

A similar recommendation has been madepreviously, for another monoclonal antibody drug, casirivimab-imdevimab, and the experts say there is insufficient data to recommend one over the other.

For both, the effectiveness against new variants, like Omicron, is still uncertain. 

The group will update their guidelines for monoclonal antibodies when more data becomes available.

Recommendations

These recommendations are based on new evidence from seven trials involving over 4,000 patients with non-severe, severe, and critical infections.

Developed by WHO with the methodological support of MAGIC Evidence Ecosystem Foundation, the guidelinesprovide trustworthy guidance and help doctors make better decisions with their patients.

According to the agency, the guidelines are useful in fast moving research areas, because they allow researchers to update evidence summaries as new information becomes available.

The latest guidance also updates recommendations for the use of interleukin-6 receptor blockers and systemic corticosteroids for patients with severe or critical COVID-19; conditional recommendations for the use of casirivimab-imdevimab (another monoclonal antibody treatment) in selected patients; and against the use of convalescent plasma, ivermectin and hydroxychloroquine, regardless of disease severity.

Continue Reading

Publications

Latest

Eastern Europe3 hours ago

Ukraine Lies About 2022 Russian Attack to Hide Dying Economy

Yesterday, Ukraine’s president Zelensky speaking to the Ukrainian Foreign Intelligence Service said “We have learned to contain external threats. It...

Reports10 hours ago

Structural Reforms Needed to Put Tunisia on Path to Sustainable Growth

Decisive structural reforms and an improved business climate are essential to put Tunisia’s economy on a more sustainable path, create...

Development12 hours ago

‘Global learning crisis’ continues says Guterres; millions still hit

Almost two years into the COVID-19 pandemic, school closures continue to disrupt the lives of over 31 million students, exacerbating what...

Middle East15 hours ago

Ukraine crisis could produce an unexpected winner: Iran

 Iran potentially could emerge as an unintended winner in the escalating crisis over Ukraine. That is, if Russian troops cross...

Finance15 hours ago

How Twitter can help your business

Twitter is easily one of the leading online platforms which encourages networking on a global scale. The number of users,...

Economy17 hours ago

2022: Rise of Economic Power of Small Medium Businesses across the World

Why mirrors of the Wall: To fight obesity a life-sized mirror required, to uplift the national economy a simple calculator is...

Reports19 hours ago

Lebanon’s Crisis: Great Denial in the Deliberate Depression

The scale and scope of Lebanon’s deliberate depression are leading to the disintegration of key pillars of Lebanon’s post-civil war...

Trending